We draw on scientists and entrepreneurs with comprehensive experience and deep relationships.
Chris Adams, PhD, MBA
Founder and Chief Executive Officer
Chris has more than 20 years’ experience in ensuring patient impact drives all aspects of the business side of orphan drug development, including business strategy, commercial planning, licensing and mergers and acquisitions.
Before co-founding Cydan in 2013, Chris was president of CMA Biotech Consulting, which primarily served development stage orphan drug companies. He also was chief business officer of FoldRx Pharmaceuticals Inc., where he played an instrumental role in the company being acquired by Pfizer in 2010. He also served as senior vice president of business development for ViaCell Inc., VP of business development for Transkaryotic Therapies Inc., and director of business development for the pharmaceutical division of Ciba-Geigy Limited, in Basel, Switzerland.
He holds a PhD in organic chemistry and a diploma in organic chemistry and biochemistry from the University of Zurich, and an MBA from INSEAD of Fontainebleau, France.
Mette Kirstine Agger, MBA
Managing Partner, Lundbeckfond Ventures
Mette Kirstine was previously co-founder and CEO of 7TM Pharma A/S and has a broad international experience within biotech/life science covering business development and licensing, management and financing. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her career as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.
Mette is a board member of Cydan Development, Psioxus, scPharmaceuticals, Thesan Pharmaceuticals, Veloxis and Vtesse.
Barbara J. Dalton, PhD
Vice President of Venture Capital, Pfizer Venture Investments
Barbara Dalton joined Pfizer in 2007 to manage the Pfizer Ventures Investments team within Worldwide Business Development. She is responsible for growing their corporate venture activities, managing the corporation’s private equity portfolio, advising on structured equity transactions and driving novel transactions to achieve corporate objectives. Dr. Dalton has more than 20 years of corporate venture capital experience in the pharmaceutical industry supporting and managing teams involved in indirect and direct health care investments in more than 40 funds and over 100 companies in the U.S. and Europe. She has had direct investing responsibility for biotechnology therapeutic and platform companies, as well as some healthcare IT and service businesses. She is currently on the board of Cydan, Vtesse, Ixchelsis, The Accelerator Crop, Petra and Lodo and supports several other PVI portfolio companies as a board observer. Dr. Dalton began her pharmaceutical career as a research scientist in immunology at SmithKline and French Laboratories and joined their venture capital group, SR One, Limited in the early 1990’s. She was also a founding member and General Partner with EuclidSR Partners, a private venture capital firm, where SmithKline (now GSK) was a leading limited partner.
Dr. Dalton has also been supportive of the many regional and national organizations encouraging innovative startups in health care. She chaired the Philadelphia regional venture investors association, (fka the MAC Alliance), and has been a member of the National Venture Capital Association Board. She also supported the venture philanthropy efforts of the Institute for the Study of Ageing as a Board member. Currently she is the chair of the advisory board for the health care sector of the New York City Investment Fund and an advisor to the Dean of the Eberly College of Science, at Penn State where she received her undergraduate degree. She received a PhD in microbiology and immunology from The Medical College of Pennsylvania (now the Drexel University College of Medical School).
Carl Goldfischer, MD
Investment Partner & Managing Director, Bay City Capital
Carl Goldfischer, MD, is an Investment Partner and Managing Director of Bay City Capital and has been with the firm since 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer serves on the board of directors of numerous companies, including EnteroMedics, Epizyme, Metabolex, and Pharmakea Therapeutics. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.
Joel S. Marcus, Board Observer
Chairman, Chief Executive Officer & Founder, Alexandria Real Estate Equities, Inc.
Joel S. Marcus has served as Chairman of Alexandria Real Estate Equities’ Board of Directors since May 2007, Chief Executive Officer since March 1997, President since February 2009 and a Director since the Company’s inception in 1994. Mr. Marcus co-founded Alexandria Real Estate Equities, Inc. in 1994, Alexandria Venture Investments in 1996, and the annual Alexandria Summit in 2011.
Previously, Mr. Marcus was a partner at the law firm of Brobeck, Phleger & Harrison LLP, specializing in corporate finance and capital markets, venture capital and mergers and acquisitions. He also served as General Counsel and Secretary of Kirin-Amgen, Inc., a joint venture that financed the development of, and owned patents to, two multibillion dollar genetically engineered biopharmaceutical products. Mr. Marcus was formerly a practicing certified public accountant and tax manager with Arthur Young & Co. specializing in the financing and taxation of REITs.
Mr. Marcus serves on the Boards of the Accelerator Corporation, of which he was one of the original architects and co-founders, Foundation for the National Institutes of Health (FNIH), Intra-Cellular Therapies, Inc., Multiple Myeloma Research Foundation (MMRF) and the Partnership for New York City. Mr. Marcus received the Ernst & Young 1999 Entrepreneur of the Year Award (Los Angeles – Real Estate).
Mr. Marcus received his undergraduate and JD degrees from the University of California, Los Angeles.
David M. Mott, Chairman
General Partner, New Enterprise Associates
Dave Mott joined New Enterprise Associates in September 2008 as a General Partner primarily focused on biopharmaceutical investments. Dave leads NEA’s healthcare investing practice which typically comprises 30% to 40% of each fund, or roughly $750 million to $1 billion of healthcare venture investments every three to four years. The firm invests across all stages and geographies and is a leading investor across all healthcare sectors.
Prior to joining NEA, Dave was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Dave joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and from 2000 – 2008 Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Dave founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Prior to joining MedImmune, Dave was a Vice President in Health Care Investment Banking at Smith Barney, Harris Upham & Co., Inc. where he focused on public and private equity and debt financings as well as mergers and acquisitions. He received a bachelor of arts degree in economics and government from Dartmouth College.
Dave is currently Chairman of 3-V Biosciences, Ardelyx, Cydan, Mersana, Prosensa, TESARO, and Zyngenia and is a director of Adaptimmune, Edimer Pharmaceuticals, and Epizyme. He has previously been a director of MedImmune, Shire Pharmaceuticals, Ambit Pharmaceuticals, Omthera Pharmaceuticals, Rib-X Pharmaceuticals and Conceptis.
Sara Nayeem, MD
Partner, New Enterprise Associates
Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Mersana, Cydan, Vtesse and Therachon, and as a board observer for Loxo Oncology (LOXO), Ziarco, Clementia, Millendo, and NightstaRx. She previously served as a board observer for Tesaro (TSRO), Epizyme (EPZM), Omthera (acquired by AstraZeneca), and Zyngenia. She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), 3-V Biosciences, Edimer, XTuit, and Proteostasis.
Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration.
Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.